Buscar
Climb Bio Inc
CLYMAñadir a la lista de seguimiento
12.900USD
-0.390-2.93%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
616.21MCap. mercado
PérdidaP/E TTM
Más Datos de Climb Bio Inc Compañía
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Información de Climb Bio Inc
Símbolo de cotizaciónCLYM
Nombre de la empresaClimb Bio Inc
Fecha de salida a bolsaAug 10, 2021
Director ejecutivoBrennan (Aoife M)
Número de empleados17
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 10
Dirección20 William Street
CiudadWELLESLEY HILLS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02481
Teléfono18668572596
Sitio Webhttps://climbbio.com/
Símbolo de cotizaciónCLYM
Fecha de salida a bolsaAug 10, 2021
Director ejecutivoBrennan (Aoife M)
Ejecutivos de Climb Bio Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
85.98K
+44.02%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Climb Bio Inc?
Los cinco principales accionistas de Climb Bio Inc son: Dr. Aoife M. Brennan
¿Cuántas instituciones poseen acciones de Climb Bio Inc (CLYM)?
A fecha de 2026Q1, 194 instituciones poseen acciones de Climb Bio Inc, con un valor de mercado combinado de aproximadamente 35.98M, lo que representa el 59.67% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -6593711.00.